# Strides Pharma Science Limited (STAR)

> STAR closed at ₹1,068.80 on 30 Oct 2026, trailing P/E 16.0, market cap ₹9,851 cr, latest results for the quarter ended 30 Sept 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Strides Pharma Science Limited (NSE: STAR) closed at ₹1,068.80 on 30 Oct 2026, +33.8% over one year, against a 52-week range of ₹768.65 – ₹1,260.90.

In the quarter ended 30 Sept 2026 (consolidated, filed 29 Oct 2026) it reported revenue of ₹1,430 cr and net profit of ₹131 cr, a 9.2% net margin; revenue grew 17.1% and profit fell 3.0% year on year.

On four consecutive filed quarters its trailing P/E is 16.0; since 22 May 2025 its own P/E has ranged from 14.3 to 22.4 (median 18.8), and today's reading is higher than 17% of those 356 trading days.

From the balance sheet dated 30 Sept 2026: return on equity 15.3%, ROCE 18.0%, debt-to-equity 0.54, Piotroski F-score 7 of 9.

Against 65 Healthcare peers on NSE: Net margin higher than 22% of 63 sector peers; PBT margin higher than 16% of 63 sector peers; ROE higher than 59% of 63 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹1,068.80 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -11.1% / +0.2% / +33.8% |
| 52-week low – high | ₹768.65 – ₹1,260.90 |
| Market capitalisation | ₹9,851 cr |
| Trailing P/E | 16.0 |
| Price / book | 2.88 |
| EV / EBITDA | 10.2 |
| Earnings yield | 6.3% |
| TTM EPS | ₹66.92 |
| TTM net profit | ₹617 cr |
| Quarter revenue | ₹1,430 cr |
| Quarter net profit | ₹131 cr |
| Net margin | 9.2% |
| Revenue growth (YoY) | +17.1% |
| Profit growth (YoY) | -3.0% |
| Return on equity | 15.3% |
| ROCE | 18.0% |
| Debt / equity | 0.54 |
| Current ratio | 1.29 |
| Free cash flow | ₹-160 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹23.1 cr |

## Questions

### What is the P/E ratio of Strides Pharma Science Limited?

Strides Pharma Science Limited's trailing P/E is 16.0, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 22 May 2025 its P/E has ranged 14.3–22.4.

### What were Strides Pharma Science Limited's latest quarterly results?

For the quarter ended 30 Sept 2026, Strides Pharma Science Limited reported revenue of ₹1,430 cr and net profit of ₹131 cr (consolidated), filed with the exchange on 29 Oct 2026.

### What is Strides Pharma Science Limited's ROE?

Return on equity is 15.3% based on the balance sheet dated 30 Sept 2026.

### Does Strides Pharma Science Limited have debt?

Debt-to-equity is 0.54 on the balance sheet dated 30 Sept 2026.

### What is STAR's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, STAR traded between ₹768.65 and ₹1,260.90.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/STAR

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._